CRISPR Therapeutics (CRSP) Plunges 9% After Releasing Gene Edited Drug

The company said it will start a Phase 2 study of its gene-edited drug candidate for the treatment of cancer. CRSP stock plummets 9.62% in the pre-market to $92.70. For the study, which was conducted on 26 patients, the company gave the drug for 28 days. The results were impressive. After seeing a pop in the regular session, CRSP stock gave back some of its gains in the after-hour. For now, the company is using patient-specific cells. It uses its CRISPR technology to transform them into a customized version of a gene.

A clinical study conducted by Crispr showed that CTX110 could provide patients with B-cell non-Hodgkin’s lymphomas an off-the-shelf treatment that is similar to CAR-T. Crispr’s drug appears to be safe despite its side effects. However, a rare syndrome known as cytokine release syndrome was observed in a small number of participants. Following the positive results of its study, Crispr Pharmaceuticals is planning to expand the study to 2022 and gather more evidence for its approval.

Anthony Gonzales

Biotech, Tech, and Crypto reporterAnthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.